This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.
Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes:
PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.
PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.
Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.
For further information, read detailed Research Reports
------------------------------------------------------------------------------------------------------------------------------------------------------
Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, pvct.com, a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application.
The "Provectus IR" App is available for download from the App Store at www.itunes.com/appstore and from the Google Play Store at play.google.com. The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.
-------------------------------------------------------------------------------------------------------------------------------------------------------
Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"
pvct.com
August 19, 2008
PV-10 for Melanoma Story Airs on ABC's 7:30 Report in Australia
The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story on the treatment of melanoma with PV-10.
pvct.com
PVCT on YouTube...
youtube.com
theze.cn
--------------------------------------------------------------
PVCT insiders transactions:
secform4.com
--------------------------------------------------------------
Contact Info
Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com
Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP
Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302
Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com
Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com
Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031
--------------------------------------------------------------
Company Website
pvct.com
============================================================== |
